Sellas Life Sciences Group Inc (SLS) Stock Analysis
Verdict: WATCH (do not buy)
Pivotal Phase 3 REGAL readout in AML offers binary upside backed by a $138.4M cash runway, but zero revenue and trial delays keep risks speculative.
Investment score: 46/100
Analysis as of
Is Sellas Life Sciences Group Inc stock worth reviewing? AI model thesis
SELLAS Life Sciences trades at $11.34 USD with a $2.29B market cap, backed by $138.44M in cash and a 4-year runway. The model views the stock as a binary play on the Phase 3 REGAL trial readout for lead asset galinpepimut-S in AML.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 50/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Sellas Life Sciences Group Inc opportunities and risks
What speaks for SLS
- Pivotal Phase 3 REGAL Trial Readout in AML
What speaks against SLS
- Binary Clinical Failure of Lead Asset GPS
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SLS | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.3% |
| RXRX | n/a | 44.3x | n/a | -46.7% | -945.9% | -14.6% |
| CLDX | n/a | 18419.9x | n/a | -56850.9% | -268385.7% | -11.7% |
| IRON | n/a | 0.0x | n/a | 0.0% | 0.0% | -8.3% |
| NRIX | n/a | 63.8x | n/a | -165.5% | -928.4% | -13.0% |
| VRDN | n/a | 29.0x | n/a | 99.6% | -544.1% | -16.2% |
| Peer median | n/a | 44.3x | n/a | -46.7% | -928.4% | -13.0% |
Frequently asked questions about Sellas Life Sciences Group Inc (SLS)
Is SLS stock a good investment?
The cached TradeMates AI model rates Sellas Life Sciences Group Inc as WATCH (do not buy) with an investment score of 46/100. SELLAS Life Sciences trades at $11.34 USD with a $2.29B market cap, backed by $138.44M in cash and a 4-year runway. The model views the stock as a binary play on the Phase 3 REGAL trial readout for lead asset galinpepimut-S in AML. This is algorithmic model output, not personal investment advice.
Is SLS stock a buy?
The TradeMates model verdict for SLS is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.